Citations

Clear

1325 citation(s) found for "Mayo, Angela".

Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma
Abdallah, Nadine , Kapoor, Prashant , Gertz, Morie A. , Lacy, Martha Q. , Hayman, Suzanne R. , Dingli, David , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Lin, Yi , Kourelis, Taxiarchis , Warsame, Rahma , Siddiqui, Mustaqeem , Lust, John A., Kyle, Robert A. , Bergsagel, Leif, Greipp, Patricia T. , Kumar, Shaji , Bergsagel, P. Leif , Bergsagel, P. Leif , Gertz, Morie A , Lust, John, Greipp, Patricia, Siddiqui, Mustaqeem A , Dingli, David , Greipp, Patricia T , Lin, Yi , Baughn, Linda B. , Rajkumar, S. Vincent , Dispenzieri, Angela , Buadi, Francis K. , Go, Ronald S. , Leung, Nelson , Ketterling, Rhett P.

Mayo Clinic

Clinical Cancer Research | October 2, 2020 | Volume: 26 | Issue: 24 | Pages: 6581-6588

10.1158/1078-0432.ccr-20-2283 | PMID 33008815 Get It

Abstract Purpose: Rearrangements involving the MYC protooncogene are common in newly diagnosed multiple myeloma, but their prognostic significance is still unclear. The purpose of this study was to assess the impact of MYC rearrangement on clinical characteristics, treatment response, and survival in patients with newly diagnosed multiple myeloma. Experimental Design: This is a retrospective study including 1,342 patients seen in Mayo Clinic in Rochester, MN, from January 2006 to January 2018, who had cytogenetic testing by FISH at diagnosis, including MYC testing using the break apart FISH probe (8q24.1). Results: A rearrangement involving MYC was found in 8% of patients and was associated with elevated β2-microglobulin, ≥50% bone marrow plasma cells, IgA multiple myeloma, and the cooccurrence of trisomies. There were no differences in overall response rates between patients with and without MYC rearrangement when induction chemotherapy was proteasome inhibitor (PI)-based, immunomodulatory drug (IMiD)-based or PI + IMiD-based. Overall survival was shorter in patients with MYC rearrangement compared with patients without MYC rearrangement (5.3 vs. 8.0 years, P < 0.001). MYC rearrangement was associated with increased risk of death on multivariate analysis when high-risk cytogenetic abnormalities, ISS stage III, and ≥70 years of age were included (risk ratio: 1.5; P = 0.007). Conclusions: MYC rearrangement is associated with high disease burden and is an independent adverse prognostic factor in patients with newly diagnosed multiple myeloma.
Systemic amyloidosis from A (AA) to T (ATTR): a review
Muchtar, Eli , Magen, Hila , Grogan, Martha , Mauermann, Michelle L. , Kurtin, Paul J. , Dingli, David , Kumar, Shaji , Muchtar, E , Dispenzieri, Angela , Kumar, Shaji K , Gertz, Morie A , Dingli, David , Mauermann, Michelle L , Dispenzieri, Angela , McPhail, Ellen Darcy , Leung, Nelson , Buadi, Francis K. , Gertz, Morie A.

Mayo Clinic

Journal of Internal Medicine | September 18, 2020 | Volume: 289 | Issue: 3 | Pages: 268-292

10.1111/joim.13169 | PMID 32929754 Get It

Abstract Systemic amyloidosis is a rare protein misfolding and deposition disorder leading to progressive organ failure. There are over 15 types of systemic amyloidosis, each caused by a different precursor protein which promotes amyloid formation and tissue deposition. Amyloidosis can be acquired or hereditary and can affect various organs, including the heart, kidneys, liver, nerves, gastrointestinal tract, lungs, muscles, skin and soft tissues. Symptoms are usually insidious and nonspecific resulting in diagnostic delay. The field of amyloidosis has seen significant improvements over the past decade in diagnostic accuracy, prognosis prediction and management. The advent of mass spectrometry‐based shotgun proteomics has revolutionized amyloid typing and has led to the discovery of new amyloid types. Accurate typing of the precursor protein is of paramount importance as the type dictates a specific management approach. In this article, we review each type of systemic amyloidosis to provide the practitioner with practical tools to improve diagnosis and management of these rare disorders.
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease
Fajgenbaum, David C. , Wu, David , Goodman, Aaron M. , Chadburn, Amy , Srkalović, Gordan , Leitch, Heather A. , Jayanthan, Raj , Schey, Steve , Oksenhendler, Éric , Lechowicz, Mary Jo , Hoffmann, Christian , Pemmaraju, Naveen , Bagg, Adam , Lim, Megan S. , group, the Castleman Disease Collaborative Network Scientific Advisory Board diagnostic criteria international working group and treatment guidelines international working, Wong, Raymond S M , Ferrero, Simone , Dispenzieri, Angela , Zinzani, Pier Luigi , van Rhee, Frits , Fajgenbaum, David C , Lim, Megan S , Wong, Raymond , Nasta, Sunita , Mukherjee, Sudipto , Ferrero, Simone , Sato, Yasuharu , Dispenzieri, Angela , Zinzani, Pier Luigi , Fosså, Alexander , Rhee, Frits van , group, the Castleman Disease Collaborative Network Scientific Advisory Board diagnostic criteria international working group and treatment guidelines international working

Mayo Clinic

American Journal of Hematology | September 16, 2020 | Volume: 95 | Issue: 12 | Pages: 1553-1561

10.1002/ajh.25992 | PMID 32894785 Get It

AbstractIdiopathic multicentric Castleman disease (iMCD) is a rare immunologic disorder characterized by systemic inflammation, multicentric lymphadenopathy, and organ dysfunction. Enlarged lymph nodes demonstrate a spectrum of characteristic but variable histopathologic features historically categorized into hyaline vascular (HV) (or hypervascular [HyperV] more recently), plasmacytic, or “mixed.” Though the etiology is unknown, a pro‐inflammatory cytokine storm, often involving interleukin‐6 (IL‐6), contributes to pathogenesis. Anti‐IL‐6 therapy with siltuximab is the only FDA‐ or EMA‐approved treatment based on efficacy and safety in multiple studies. Importantly, no patients considered to have HV histopathology achieved the primary endpoint in the Phase II study. NCCN currently recommends siltuximab first‐line for iMCD, except for patients considered to have HV histopathology. We investigated whether histopathologic subtype should guide siltuximab treatment decisions. Secondary analyses of clinical trial and real‐world data revealed similar clinical benefit across histopathologic subtypes. Notably, only 18 of 79 patients in the Phase II study were consistently classified into histopathologic subtype by three independent review panels, demonstrating limited reliability to guide treatment decisions. Real‐world data further demonstrate siltuximab's effectiveness in patients considered to have HV (or HyperV). Though histopathology is a critical component for diagnosis, there is insufficient evidence to guide treatment based solely on lymph node histopathologic subtype.
Impact of dexamethasone responsiveness on long-term outcome in patients with newly diagnosed myeloma
Sinha, Shirshendu , Lacy, Martha Q. , Hayman, Suzanne R. , Baudi, Francis K., Lust, John A., Kumar, Shaji , Rajkumar, S. Vincent , Dispenzieri, Angela , Greipp, Patricia T. , Gertz, Morie A.

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: 8603-8603

10.1200/jco.2009.27.15_suppl.8603 Get It

8603 Background: Steroids, primarily dexamethasone (Dex), remains an integral part of the therapy for myeloma. Prior to the advent of novel agents, Dex as a single agent was demonstrated to produce overall response rates of around 50%. The toxicity associated with pulsed high dose Dex has led to this approach being abandoned. This study investigates whether responsiveness to Dex correlates with biological qualities of the plasma cell clone that predicts outcome. Methods: We identified from our prospectively maintained database, patients with newly diagnosed myeloma, who were seen at Mayo Clinic within 30 days of diagnosis and were treated with single agent Dex. The M-protein measurements and responses were assessed using the IMWG criteria. Results: 182 patients seen between March 1998 and June 2007, initially treated with single agent Dex for at least 4 weeks, were included in the analysis. The median age at diagnosis was 63 (range; 39–81) and 59% were male. The actuarial median survival for the entire group was 55 months. The median duration of Dex therapy was 15 weeks (range; 4–193). Ninety one (50%) had a partial response or better and 11 (6%) were not evaluable, with the remaining patients (44%) having less than PR or progression. 10 patients (5%) achieved a VGPR or CR. The median overall survival from diagnosis for the 91 responders was 75 months compared to 71 months for the remaining patients; p = 0.6. There was no correlation between baseline disease characteristics and Dex responsiveness. One hundred thirty (70%) patients proceeded to an autologous SCT after a median of 15 weeks (range 1–46 months) of Dex. While the median overall survival was longer among the group of patients who underwent SCT, among either group, there were no survival benefit between those with a PR or better to Dex compared to the rest. Conclusions: Among this group of patients with newly diagnosed myeloma treated with single agent Dex, failure to respond to Dex induction therapy did not impact overall survival. Failure to respond to single agent steroid does not have an adverse impact on outcome in newly diagnosed myeloma. [Table: see text]
Natural history of multiple myeloma (MM) relapsing after autologous stem cell transplantation (ASCT)
Madan, Sumit , Lacy, Martha Q. , Hayman, S. R., Kumar, Santosh , Dispenzieri, Angela , Buadi, Francis K. , Dingli, David , Rajkumar, S. Vincent , Gertz, Morie A.

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: e19513-e19513

10.1200/jco.2009.27.15_suppl.e19513 Get It

e19513 Background: The outcome of patients with MM relapsing after ASCT used early in the disease course or after failure of initial therapy, is not well defined. We undertook this study to understand treatment approaches for patients relapsing after single ASCT. Methods: Patients relapsing after single ASCT were identified from a prospectively maintained database and relevant clinical data were extracted from medical records. Relapse and treatment responses were according to IMWG Uniform Response Criteria. Patients relapsing between Jan 2000 and 2008 were included in order to capture a recent cohort contemporaneous to availability of novel drugs. Results: We studied 487 patients who had relapsed following a single ASCT, of whom 351 (72%) had an early SCT (≤ 12 mos from diagnosis). The median estimated follow up for all patients was 27 mos, 50 mos and 69 mos from relapse, SCT and diagnosis respectively. The median overall survival (OS) from the time of relapse was 30 mos for the early SCT group and 21 months for the late SCT group. The median time to relapse following transplant was 15 mos (3–119) among early SCT group and 12 mos (3–76) among the late SCT group. Longer time to relapse as well as longer time from relapse to initiation of therapy were independent predictors of better outcome. Among the early group, nearly a third of the patients achieved a PR or better to first salvage therapy (Table), with another third achieving stable disease and 25% of patients did not have response data. The median progression free survival for the first salvage regimen was 8 mos; 18 mos for those with PR or better and 5 mos for those with SD as the best response. Data on the regimen 2, 3, 4, 5, and 6 were available for 211, 133, 84, 53 and 28 patients respectively. As expected, the response rates and the response duration decreased with increasing number of relapses. Conclusions: Patients relapsing after ASCT can obtain prolonged response duration with the currently available treatments. Those with a durable response to transplant and those not requiring initiation of therapy for long periods after disease relapse have favorable disease biology and have prolonged survival after relapse. The natural history of the disease provides a valuable benchmark for evaluation of newer treatment approaches. No significant financial relationships to disclose.
Low risk for symptomatic venous thromboembolic events (vte) during cytokine administration for peripheral blood stem cell mobilization
Naina, Harris, Pruthi, Rajiv K. , Litzow, Mark R. , Ansell, Stephen M. , Hogan, WJ, Elliott, M. A., Gastineau, Dennis A. , Kumar, Shaji , Dispenzieri, Angela , Hogan, W. J., Gertz, Morie A.

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: 7039-7039

10.1200/jco.2009.27.15_suppl.7039 Get It

7039 Background: Erythropoiesis-stimulating agents are known to increase the risk for VTE events, especially in patients with underlying malignancies. However, there is a paucity of information on other hematopoietic growth factors such as granulocyte colony-stimulating factor (GSCF) granulocyte-macrophage colony stimulating factor (GM-CSF) AMD 3001 and risk for VTE. Methods: Between January 2000 and October 2008, a total of 631 patients underwent peripheral blood stem cell mobilization (PBSCM) using either GCSF, GMCSF, cyclophosphamide, AMD 3100, or with any of the above combination. We included only patients with a diagnosis of AL amyloidosis (AL), multiple myeloma (MM) Hodgkin's lymphoma (HL) and non Hodgkin's lymphoma (NHL). Patients’ demographic details and diagnosis of VTE were collected from electronic medical records. Results: Of the 631 patients who underwent PBSCM the median age of the patients was 57 years (range 17–77). 448 patients (71%) received single agent GCSF, 82 (13%) received combination of GMCSF and cyclophosphamide, 52 (8%) received cyclophosphamide and GCSF, 30 patients received a combination of GMCSF and GCSF, 10 (1.5%) patients received GCSF and AMD 3100. Of the 631 patients, 278 (44%) MM, 209 (33%) NHL, 114 (18%) AL, and 20 (3%) had HL. We found 7 (1.1%) patients with symptomatic VTE occurring between administration of growth factors and stem cell transplant. The median duration from the administration of growth factors to detection of VTE was 5 days (range 1–30). Two AL,3 MM and 2 NHL. Of the 7 patients, 2 patients had pulmonary embolism and 1 patient developed deep vein thrombosis. Two patients with AL developed heparin induced thrombocytopenia (HIT). The remaining 4 patients developed symptomatic catheter related thrombosis. Only 1 patient had past history of VTE. Of the 7 patients, 5 received GCSF alone, 1 received GMCSF, and cyclophosphamide, 1 received GCSF and cyclophosphamide. Of the 4 patients who developed catheter related thrombosis, catheter was removed in 2 patients. None of the patients developed VTE related morality. Conclusions: The risk for symptomatic VTE during PBSCM is low. HIT should be considered as a possible cause for VTE in patients undergoing PBSCM. No significant financial relationships to disclose.
Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement
Hogan, Marie C. , Chamberlin, Julie A., Vaughan, Lisa E. , Waits, Angela L., Banks, Carly J., Leistikow, Kathleen, Oftsie, Troy, Madsen, Chuck D, Edwards, Marie E., Glockner, James F., Kremers, Walter K. , Harris, Peter C. , Torres, Vicente E. , Banks, Carly, Madsen, Chuck, Edwards, Marie, Glockner, James, Torres, Vicente E , Masyuk, Tatyana V. , Harris, Peter C , Torres, Vicente E , Kremers, Walter K , Hogan, Marie C , Leistikow, Kathleen, LaRusso, Nicholas F.

Mayo Clinic

Clinical Journal of the American Society of Nephrology | August 25, 2020 | Volume: 15 | Issue: 9 | Pages: 1267-1278

10.2215/cjn.13661119 | PMID 32843370 Get It

Background and objectives We assessed safety and efficacy of another somatostatin receptor analog, pasireotide long-acting release, in severe polycystic liver disease and autosomal dominant polycystic kidney disease. Pasireotide long-acting release, with its broader binding profile and higher affinity to known somatostatin receptors, has potential for greater efficacy. Design, setting, participants, & measurements Individuals with severe polycystic liver disease were assigned in a 2:1 ratio in a 1-year, double-blind, randomized trial to receive pasireotide long-acting release or placebo. Primary outcome was change in total liver volume; secondary outcomes were change in total kidney volume, eGFR, and quality of life. Results Of 48 subjects randomized, 41 completed total liver volume measurements ( n =29 pasireotide long-acting release and n =12 placebo). From baseline, there were −99±189 ml/m absolute and −3%±7% change in annualized change in height-adjusted total liver volume (from 2582±1381 to 2479±1317 ml/m) in the pasireotide long-acting release group compared with 136±117 ml/m absolute and 6%±7% increase (from 2387±759 to 2533±770 ml/m) in placebo ( P <0.001 for both). Total kidney volumes decreased by −12±34 ml/m and −1%±4% in pasireotide long-acting release compared with 21±21 ml/m and 4%±5% increase in the placebo group ( P =0.05 for both). Changes in eGFR were similar between groups. Among the n =48 randomized, adverse events included hyperglycemia (26 of 33 [79%] in pasireotide long-acting release versus four of 15 [27%] in the placebo group; P <0.001), and among the 47 without diabetes at baseline, 19 of 32 (59%) in the pasireotide long-acting release group versus one of 15 (7%) in the placebo group developed diabetes ( P =0.001). Conclusions Another somatostatin analog, pasireotide long-acting release, slowed progressive increase in both total liver volume/total kidney volume growth rates without affecting GFR decline. Participants experienced higher frequency of adverse events (hyperglycemia and diabetes). Clinical Trial registry name and registration number Pasireotide LAR in Severe Polycystic Liver Disease, NCT01670110 Podcast This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2020_08_28_CJN13661119.mp3
ASSOCIATION BETWEEN CHOROIDAL CHARACTERISTICS AND SYSTEMIC SEVERITY IN AMYLOIDOSIS
Mano, Fukutaro , Pavésio, Carlos , Khalid, Hagar , Keane, Pearse A. , Pulido, José S. , Dispenzieri, Angela , Kusaka, Shunji

Mayo Clinic

Retina | August 21, 2020 | Volume: 41 | Issue: 5 | Pages: 1037-1046

10.1097/iae.0000000000002961 | PMID 32826787 Get It

Purpose: This study aimed to describe the choroidal features of ocular amyloidosis using multimodal imaging, to correlate these findings with systemic involvement, and to propose a choroidal grading system. Methods: Eleven patients with systemic amyloidosis were reviewed retrospectively. Each case was assigned a grade according to the severity of choroidal findings as determined by both enhanced depth imaging optical coherence tomography and indocyanine green angiography. The severity of systemic amyloidosis was then correlated with the choroidal involvement. Results: On indocyanine green angiography, all patients exhibited hyperfluorescent spots in the late stage and were classified according to preexisting criteria. On enhanced depth imaging optical coherence tomography, hyperreflective foci were seen in the choriocapillaris and Sattler's layer in Grade 1, partial loss of Sattler's layer was additionally seen in Grade 2, and a dense hyperreflective Haller's layer was seen in Grade 3. Choroidal grading scores were significantly correlated with the systemic severity score (P = 0.0014, Pearson's correlation coefficient; ρ = 0.83). Conclusion: With ocular amyloidosis, evaluation of choroidal characteristics using multimodal imaging may serve as a biomarker for systemic involvement.
Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab
Kohlhagen, Mindy , Dasari, Surendra , Hetrick, MeLea, Netzel, Brian C., Murray, David , Willrich, Maria, Netzel, Brian, Murray, David L., Willrich, Maria Alice V. , Dispenzieri, Angela

Mayo Clinic

Clinical Chemistry and Laboratory Medicine (CCLM) | August 17, 2020 | Volume: 59 | Issue: 1 | Pages: 155-163

10.1515/cclm-2020-0581 | PMID 32745067 Get It

Abstract Objectives A matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) method (Mass-Fix) as a replacement for gel-based immunofixation (IFE) has been recently described. To utilize Mass-Fix clinically, a validated automated method was required. Our aim was to automate the pre-analytical processing, improve positive specimen identification and ergonomics, reduce paper data storage and increase resource utilization without increasing turnaround time. Methods Serum samples were batched and loaded onto a liquid handler along with reagents and a barcoded sample plate. The pre-analytical steps included: (1) Plating immunopurification beads. (2) Adding 10 μl of serum. (3) Bead washing. (4) Eluting the immunoglobulins (Igs), and reducing to separate the heavy and light Ig chains. The resulting plate was transferred to a second low-volume liquid handler for MALDI plate spotting. MALDI-TOF mass spectra were collected. Integrated in-house developed software was utilized for sample tracking, driving data acquisition, data analysis, history tracking, and result reporting. A total of 1,029 residual serum samples were run using the automated system and results were compared to prior electrophoretic results. Results The automated Mass-Fix method was capable of meeting the validation requirements of concordance with IFE, limit of detection (LOD), sample stability and reproducibility with a low repeat rate. Automation and integrated software allowed a single user to process 320 samples in an 8 h shift. Software display facilitated identification of monoclonal proteins. Additionally, the process maintains positive specimen identification, reduces manual pipetting, allows for paper free tracking, and does not significantly impact turnaround time (TAT). Conclusions Mass-Fix is ready for implementation in a high-throughput clinical laboratory.
Abstract 01: Implementation of cognitive computing to match clinical trials in gynecologic cancers: A single-institution experience
Ho, Thanh P. , Helgeson, J. , Andring, Angela L., Reed, Jennifer C., Boyle, Venessa L., Leventakos, Konstantinos , Haddad, Tufia C. , Hendrickson, Andrea E. Wahner , Weroha, Saravut J., Sofiyeva, Nigar

Mayo Clinic

Clinical Cancer Research | August 11, 2020 | Volume: 26 | Issue: 12_Supplement_1 | Pages: 01-01

10.1158/1557-3265.advprecmed20-01 Get It

Abstract Objectives: Cognitive computing has the potential to improve efficiency and accuracy of clinical trial enrollment using artificial intelligence. The cognitive computing clinical trial matching (CTM) system used for this study utilizes natural language processing to derive patient and tumor attributes from structured and unstructured electronic medical record (EMR) data. The attributes are matched to complex eligibility criteria in trial protocols. This CTM system has been implemented in our gynecologic oncology practice, for which there is lower representation of ethnic minorities, elderly, and uninsured in National Cancer Institute-sponsored trials. Methods: A clinical research coordinator (CRC) used the CTM system to screen patients for potential clinical trials one day prior to their clinic visit. Trial matches were shared with gynecologic oncology clinicians to raise awareness for study opportunities and assist in treatment decisions. Clinicians were surveyed regarding their experience with the CTM system prepared matches. The identical patients were evaluated by a clinician using the traditional manual screening method. Results: Seventeen patients with new diagnosis, recent resection, or restaging scans were screened for 41 potential gynecologic, phase I, and supportive care clinical trials. Trial screening by the CRC using the CTM system resulted in a total of 119 matched trials (mean: 7 trials/patient) compared to the clinician-generated list of 271 matched trials (mean: 16 trials/patient). The CRC using the CTM system spent an average of 18 minutes/patient (range: 7 to 40 minutes) compared to the clinician average of 22 minutes/patient (range: 7 to 37 minutes). A survey of 8 gynecologic oncology clinicians reported they were willing to spend an average of 8 minutes/patient (range: 1 to 15 minutes) to screen patients for trial eligibility. On independent review, discrepancies occurred when the clinician identified trials that the CRC excluded due to inclusion/exclusion criteria or were unknowingly closed to accrual. In addition, the CRC identified trials that were inadvertently missing from the clinician’s list of active protocols. Consistent with these observations, 100% of surveyed clinicians (8 of 8) agreed that “The CTM system has helped to include and exclude trials prior to discussion with patients.” Conclusions: Use of the CTM system by a CRC was superior to a clinician alone for the accuracy and efficiency of screening clinical trial eligibility. This process improved the identification of trials that a clinician might otherwise miss and the exclusion of trials that were not available or appropriate for patients. The CTM system can reduce the burden of clinicians and research staff to screen patients. Additional research is needed to determine if the process can improve clinical trial enrollment in gynecologic cancers. Citation Format: Thanh P. Ho, Jane M. Helgeson, Angela L. Andring, Jennifer C. Reed, Venessa L. Boyle, Nigar Sofiyeva, Konstantinos Leventakos, Tufia C. Haddad, Andrea E. Wahner Hendrickson, Saravut (John) Weroha. Implementation of cognitive computing to match clinical trials in gynecologic cancers: A single-institution experience [abstract]. In: Proceedings of the AACR Special Conference on Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies; Jan 9-12, 2020; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(12_Suppl_1):Abstract nr 01.